Study of SRF231 in Patients With Advanced Solid and Hematologic Cancers

Summary

This Phase 1/1b, open-label, first-in-human, monotherapy study will be conducted in 2 parts. Part A will consist of the SRF231 monotherapy dose-escalation portion of the study, and will enroll up to 48 patients with advanced solid tumors and hematological cancers. Part B will include monotherapy expansion cohorts in advanced solid and hematologic cancers to further examine SRF231 as monotherapy (100 patients total).

Timeline

Start

2018-03-13

Primary completion

2020-09-15

Completion

2020-09-29

Drugs

Indications